5 Resilient Stocks During Market Bloodbath

4. Viking Therapeutics Inc. (NASDAQ:VKTX)

Viking Therapeutics extended its winning streak to an 8th consecutive day on Tuesday, as investors gobbled up shares amid the growing appetite for the weight loss market, thanks to Medicare’s beginning of coverage of anti-obesity treatments.

Beginning July 1, 2026, Medicare, under its GLP-1 Bridge program, will start covering anti-obesity drugs such as Foundayo, Wegovy, and Zepbound for its members.

The news sparked interest among weight loss drug manufacturers, including Viking Therapeutics Inc. (NASDAQ:VKTX), which is underway with the development of its own VK2735 for obesity and type 2 diabetes.

Medicare aside, the stock’s rally can also be partly attributed to investor funds fleeing the AI sector towards other high-growth industries.

In other news, Viking Therapeutics Inc. (NASDAQ:VKTX) announced the appointment of Hubert Chen as its new chief medical officer.

Prior to joining the company, Chen served as chief research and development officer at Loyal Animal Health, where he led the first-ever FDA-negotiated effectiveness and safety requirements for longevity therapeutics. Previously, he was president and chief scientific officer at Forte Biosciences, CMO at Metacrine, and chief scientific and medical officer at Pfenex.

As Viking Therapeutics Inc.’s (NASDAQ:VKTX) new CMO, Chen is tasked to oversee clinical development, medical, and regulatory affairs.

1281292 - 11759070 - 1